Actavis Faces Shortage of Slow-Release Alzheimer’s Drug
This article is for subscribers only.
Actavis Plc is struggling to meet demand for its Alzheimer’s drug Namenda after promoting a slow-release version of the drug ahead of a patent expiration for the traditional pill.
“We’re working as fast as we can to fix supply for the XR version,” said David Belian, an Actavis spokesman, referring to the extended-release version of Namenda.